Cargando…
A two-stage design for phase II trials with time-to-event endpoint using restricted follow-up
In phase II oncology trials, the use of new cytostatic drugs raises some questions regarding the endpoint. Time-to-event endpoints such as Progression-Free Survival have been recommended and led to new designs. In 2003, Case and Morgan proposed a design based on the comparison of the cumulative haza...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898579/ https://www.ncbi.nlm.nih.gov/pubmed/29696201 http://dx.doi.org/10.1016/j.conctc.2017.09.010 |